"Disease" from_date:2012

Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT Text onlyJournals LibraryNHS NIHR - National Institute for Health and Care ResearchSelectEMEGHRHSDRHTAPGfARPHR AdvancedJournalsEfficacy and Mechanism EvaluationGlobal Health ResearchHealth and Social Care Delivery ResearchHealth Technology cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCTToby M Maher, Veronica A Tudor, Peter Saunders, Fernando Zanghelini, Carlota Grossi Sampedro, Georgios Xydopoulos, Michael Gibbons, Sophie V Fletcher, Christopher P Denton, Maria Kokosi, Rachel K Hoyles, Helen Parfrey, Elisabetta A Renzoni, Athol U Wells, Deborah Ashby, Richard J Fordham, Matyas Szigeti

Intravascular lithotripsy for calcified arteries in peripheral arterial disease Intravascular lithotripsy for calcified arteries in peripheral arterial disease Interventional procedures guidance Published: 3 January 2024 www.nice.org.uk/guidance/ipg780 Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising to review, authorise and monitor the introduction of new devices and procedures. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. 1 Recommendations 1.1 Intravascular lithotripsy for calcified arteries in peripheral arterial disease

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management NICE guideline Published: 19 March 2024 www.nice.org.uk/guidance/ng240 © NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility ) and meningococcal disease: recognition, diagnosis and management(NG240)© NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2 of93Contents Overview ......................................................................................................................................6 Who

Cardiovascular disease: risk assessment and reduction, including lipid modification Cardiovascular disease: risk assessment and reduction, including lipid modification NICE guideline Published: 14 December 2023 www.nice.org.uk/guidance/ng238 © NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cardiovascular disease: risk

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over Technology appraisal guidance Published: 26 February 2025 www.nice.org.uk/guidance/ta1044 © NICE 2025. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years andover (TA1044)© NICE 2025. All rights reserved. Subject to Notice

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis Technology appraisal guidance Published: 20 November 2024 www.nice.org.uk/guidance/ta1018 © NICE 2024. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance represent the view of NICE inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis(TA1018)© NICE 2024. All rights reserved. Subject to Notice of rights ( 2 of26 Contents 1

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease Technology appraisal guidance Published: 23 January 2025 www.nice.org.uk/guidance/ta1035 © NICE 2025. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance authorisation, as an option for treating symptomatic anaemia caused by chronic kidney disease in adults having maintenance dialysis. Vadadustat is only recommended if the company provides it according to the commercial arrangement. 1.2 If people with the condition and their healthcare professional consider vadadustat and erythropoiesis stimulating agents (ESAs) to be suitable treatments, after discussing

Burden of injuries in Nepal, 1990 2017: findings from the Global Burden of Disease Study 2017 Burden of injuries in Nepal, 1990 2017: findings from the Global Burden of Disease Study 2017 | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu Journals Library Search Journals Library * Journals Journals * About journals * Efficacy * Editorial policies * Latest updates * For Reviewers For Reviewers * For reviewers * Become a reviewer * About Journals Library About Journals Library * About us * Support for researchers * Policies * FAQs * Contact us Close menu Global Health Research Burden of injuries in Nepal, 1990 2017: findings from the Global Burden of Disease Study 2017 1. Journals Library 2. Global Health Research 3. Burden

Ustekinumab (Stelara) - inflammatory bowel disease: ulcerative colitis and Crohn's disease Prepared by the All Wales Therapeutics and Toxicology Centre Page 1 of 9 Ustekinumab (Stelara®▼) for the treatment of inflammatory bowel disease in children and young people aged 6 to 17 years: for ulcerative colitis following loss of response, non-response or intolerance to anti-TNF therapies and vedolizumab; for Crohn’s disease following loss of response, non-response or intolerance to anti-TNF therapies (OW25) February 2023 ONE WALES INTERIM DECISION Ustekinumab (Stelara®▼) for the treatment of inflammatory bowel disease in children and young people aged 6 to 17 years: for ulcerative colitis following loss of response, non-response or intolerance to anti-TNF therapies and vedolizumab

Vedolizumab (Entyvio) - inflammatory bowel disease: ulcerative colitis and Crohn's disease Prepared by the All Wales Therapeutics and Toxicology Centre Page 1 of 8 Vedolizumab (Entyvio®) for the treatment of inflammatory bowel disease in children and young people aged 6 to 17 years: for ulcerative colitis following loss of response or non-response to anti-TNF treatment; for Crohn’s disease following loss of response or non-response to anti-TNF treatment and ustekinumab (OW24) February 2023 ONE WALES INTERIM DECISION Vedolizumab (Entyvio®) for the treatment of inflammatory bowel disease in children and young people aged 6 to 17 years: for ulcerative colitis following loss of response or non-response to anti-TNF treatment; for Crohn’s disease following loss of response or non-response

Interventions for chronic kidney disease in people with sickle cell disease. Sickle cell disease (SCD), one of the commonest severe monogenic disorders, is caused by the inheritance of two abnormal haemoglobin (beta-globin) genes. SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Kidney disease is a frequent and potentially severe complication in people with SCD. Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function present for more than three months. Sickle cell nephropathy refers to the spectrum of kidney complications in SCD. Glomerular damage is a cause of microalbuminuria and can develop at an early age in children with SCD, with increased prevalence in adulthood. In people with sickle cell nephropathy

Treatment options for Chronic Kidney Disease GP EVIDENCEHow to use this data: Key ConceptsAboutFeedbackConditionsAFAtrial FibrillationCHDCoronary Heart DiseaseCKDChronic Kidney DiseaseCOPDChronic Obstructive Pulmonary DiseaseGoutGoutHF-PEFHeart Failure with Preserved Ejection FractionHF-REFHeart Failure with Reduced Ejection FractionHypertensionHypertensionLipidsLipid lowering to prevent cardiovascular diseaseMenopauseMenopauseOsteoporosisOsteoporosisStroke and TIAStroke and TIAT2DMType 2 Diabetes MellitusTreatment options forChronic Kidney DiseaseThe definition of Chronic Kidney Disease (CKD) is wide and ranges from mild age-related changes in kidney function to severe progressive kidney disease.It is helpful to think about an individual’s risk of developing different problems related

Treatment options for Coronary Heart Disease GP EVIDENCEHow to use this data: Key ConceptsAboutFeedbackConditionsAFAtrial FibrillationCHDCoronary Heart DiseaseCKDChronic Kidney DiseaseCOPDChronic Obstructive Pulmonary DiseaseGoutGoutHF-PEFHeart Failure with Preserved Ejection FractionHF-REFHeart Failure with Reduced Ejection FractionHypertensionHypertensionLipidsLipid lowering to prevent

Treatment options for Lipid lowering to prevent cardiovascular disease GP EVIDENCEHow to use this data: Key ConceptsAboutFeedbackConditionsAFAtrial FibrillationCHDCoronary Heart DiseaseCKDChronic Kidney DiseaseCOPDChronic Obstructive Pulmonary DiseaseGoutGoutHF-PEFHeart Failure with Preserved Ejection FractionHF-REFHeart Failure with Reduced Ejection FractionHypertensionHypertensionLipidsLipid

Treatment options for Chronic Obstructive Pulmonary Disease GP EVIDENCEHow to use this data: Key ConceptsAboutFeedbackConditionsAFAtrial FibrillationCHDCoronary Heart DiseaseCKDChronic Kidney DiseaseCOPDChronic Obstructive Pulmonary DiseaseGoutGoutHF-PEFHeart Failure with Preserved Ejection FractionHF-REFHeart Failure with Reduced Ejection FractionHypertensionHypertensionLipidsLipid lowering

Health System Readiness for Disease-Modifying Therapies for Alzheimer Disease View of Health System Readiness for Disease-Modifying Therapies for Alzheimer Disease | Canadian Journal of Health Technologies Return to Article DetailsHealth System Readiness for Disease-Modifying Therapies for Alzheimer Disease

Endoluminal gastroplication for gastro-oesophageal reflux disease Endoluminal gastroplication for gastro-oesophageal reflux disease Interventional procedures guidance Published: 1 March 2023 www.nice.org.uk/guidance/ipg753 Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare disease is adequate. However, evidence on its efficacy is inadequate in quality, particularly in terms of patient selection and long-term outcomes. Therefore, this procedure should be used only in research. Find out what only in research means on the NICE interventional procedures guidance page. 1.2 Further research should include suitably powered randomised controlled trials with details of patient

Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease Interventional procedures guidance Published: 11 January 2023 www.nice.org.uk/guidance/ipg749 Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising of laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease (GORD) is adequate to support using this procedure provided that standard arrangements are in place for clinical governance, consent and audit. Find out what standard arrangements mean on the NICE interventional procedures guidance page. 1.2 Patient selection, and the procedure, should be done by clinicians who have specific

Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease Interventional procedures guidance Published: 9 August 2023 www.nice.org.uk/guidance/ipg769 1 Recommendations 1.1 Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease should be used only in research. Find out what only in research means on the NICE interventional procedures guidance page. 1.2 Further research could include the analysis of registry data or similar observational data to investigate patient selection and long-term outcomes, particularly the durability of the valve. Randomised controlled trials would also be useful

Metastatic malignant disease of unknown primary origin in adults: diagnosis and management Metastatic malignant disease of unknown primary origin in adults: diagnosis and management Clinical guideline Published: 26 July 2010 www.nice.org.uk/guidance/cg104 © NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated 26 recommendations wherever possible. Metastatic malignant disease of unknown primary origin in adults: diagnosis andmanagement (CG104)© NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated 26 April 2023Page 2of 24Contents Overview